Tuesday, November 22, 2005


Sembiosys uses debt financing for capital expansion

Sembiosys has secured 2.5 million in debt financing from Oxford Finance Corporation of Virginia for capital asset purchases. According to the press release, these capital asset purchases will triple their plant growth capacity. This expansion is needed as Sembiosys moves its insulin and Apo AI drugs from research into a commercialization phase.

<< Home

This page is powered by Blogger. Isn't yours?